sublingual buprenorphine

DRUG3 trials

Sponsors

Titan Pharmaceuticals, Thomas Jefferson University

Conditions

Neonatal Abstinence SyndromeOpioid Dependence

Phase 1

Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines

CompletedNCT01671410

Thomas Jefferson UniversityNeonatal Abstinence Syndrome

Start: 2012-08-31End: 2016-09-30Updated: 2016-10-14

Phase 3

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

TerminatedNCT00768482

Titan PharmaceuticalsOpioid Dependence

Start: 2008-09-30End: 2008-12-31Updated: 2018-12-31

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

CompletedNCT01452789

Thomas Jefferson UniversityNeonatal Abstinence Syndrome

Start: 2011-11-30End: 2016-06-30Updated: 2020-03-24

Related Papers

Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome

New England Journal of Medicine2017-05-04161 citations